Ohm, Yes. This is precisely what is baffling.
Post# of 154818
(Total Views: 794)
Posted On: 10/17/2020 12:38:47 PM
Ohm,
Yes. This is precisely what is baffling. The two main differences between Cenicriviroc (CVC) and LL is that the former is a small molecule and, apparently, also suppresses the binding of MCP-1 to CCR2b-expressing cells.
So, there are possibly two targets: either CCR5 or CCR2b, however if MCP-1 goes up it does not raise hopes for "modulating the immune response" , which is exactly what the ACTIV study is trying to achieve.
Unless "modulation" means "increasing the cytokine storm".
NP should request Leronlimab to be taken into account for these studies. ANY venue to get LL out there is valid and more with government sponsorship.
Yes. This is precisely what is baffling. The two main differences between Cenicriviroc (CVC) and LL is that the former is a small molecule and, apparently, also suppresses the binding of MCP-1 to CCR2b-expressing cells.
So, there are possibly two targets: either CCR5 or CCR2b, however if MCP-1 goes up it does not raise hopes for "modulating the immune response" , which is exactly what the ACTIV study is trying to achieve.
Unless "modulation" means "increasing the cytokine storm".
Quote:
The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation — called a “cytokine storm” — that can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications. The clinical trial aims to determine if modulating that immune response can reduce the need for ventilators and shorten hospital stays. The trial, known as ACTIV-1 Immune Modulators (IM), will determine if the therapeutics are able to restore balance to an overactive immune system.
NP should request Leronlimab to be taken into account for these studies. ANY venue to get LL out there is valid and more with government sponsorship.
(7)
(0)